Your browser doesn't support javascript.
loading
Moxonidine-in mild to moderate systemic hypertension
Medical Channel. 2001; 7 (4): 31-4
em Inglês | IMEMR | ID: emr-57606
ABSTRACT
We have recently concluded a nation wide post marketing study on efficacy and safety of Moxonidine in mild to moderate hypertensives. In all 97 patients were enrolled and out of these 87 completed a 12 weeks trial. There was an average drop of 12.9 mmHg in the DBP and 16.5 mmHg in SBP. 80% patient required a daily dose of 0.2 - 0.4 mg of Moxonidine for control of their BP In 84% of the patients completing the trial the BP changed from moderate to mild or normal or from mild toonormal. The drug was well tolerated, only 2.3% having adverse effects. We conclude that the drug studied is an effective alternate for the control of hypertension
Assuntos
Buscar no Google
Índice: IMEMR (Mediterrâneo Oriental) Assunto principal: Resultado do Tratamento / Anti-Hipertensivos Limite: Feminino / Humanos / Masculino Idioma: Inglês Revista: Med. Channel Ano de publicação: 2001

Similares

MEDLINE

...
LILACS

LIS

Buscar no Google
Índice: IMEMR (Mediterrâneo Oriental) Assunto principal: Resultado do Tratamento / Anti-Hipertensivos Limite: Feminino / Humanos / Masculino Idioma: Inglês Revista: Med. Channel Ano de publicação: 2001